Overview

Botulinum Toxin in Raynaud's Phenomenon

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to evaluate the efficacy of Botulinum toxin (BT) in the treatment of treatment refractory RP by objective and subjective measures.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborator:
American Society for Surgery of the Hand
Treatments:
Botulinum Toxins